TRVI Stock Forecast & Price Target

Trevi Therapeutics is expected to see substantial growth and success in the future due to multiple positive top-line results from various trials, ongoing clinical trials for drug development, and a strong financial position with projected runway into 2030. Additionally, the company's multi-indication approach for the treatment of various chronic cough populations positions it well in the market, with a potential addressable market of $30 billion. With the potential for FDA approval and the support of a major pharmaceutical company, GSK, Trevi's stock is undervalued and has significant upside potential for investors.

Trevi Therapeutics is a clinical-stage biopharmaceutical company that faces key challenges in the development and commercialization of Haduvio, their investigational therapy for chronic cough in patients with IPF, non-IPF ILD, and RCC. Despite promising data from their ph 2b trial, the uncertainty surrounding the success of their ph 3 trial and a potential partnership for commercialization pose significant risks and hindrances to long-term success. Additionally, the recent survey highlighting the burden of chronic cough in ILD patients further emphasizes the need for effective treatments in this market.